|
Local Law Firms Home > Product Liability Overview > Class Action > Pradaxa Attorney In September 2011, Pradaxa became the center of an examination in New Zealand after as many as five senior citizens who were Pradaxa patients allegedly passed away as a result of hemorrhaging and/or internal bleeding. An additional 36 patients supposedly sustained bouts of serious injuries such as internal bleeding and/or hemorrhaging. New Zealand media outlets announced that some families claimed the chain of events resulting in their loved ones' deaths started when they switched from warfarin to Pradaxa, and infections escalated after their conditions had worsened to the point where hospital admission was needed.
The New Zealand reports came a while after regulators in Japan asked the manufacturer of Pradaxa to notify physicians about possibly fatal bleeding and/or hemorrhaging in some Pradaxa patients. According to a letter sent by the country’s health ministry to Boehringer Ingelheim, between March 14 and August11, 81 senior citizens taking Pradaxa were victims of heavy bleeding and/or hemorrhaging, resulting in five fatalities. Japanese officials recommended that patients exceeding the age of 70 may require a lower dosage of Pradaxa. Bleeding or hemorrhaging is also a negative effect of older blood thinners, including warfarin. However, warfarin bleeding can be treated with vitamin K. There is no remedy available for bleeding that results from Pradaxa and comparable medications, referred to as direct thrombin inhibitors. Did you know? Recently, worries about Pradaxa’s heart and bleeding side effects have increased, resulting in people to question whether its dangers outweigh its advantages. Pradaxa was approved in 2010 by the U.S. Food & Drug Administration (FDA), and was anticipated to substitute warfarin, a decades-old anti-clotting medication. |